Catalyst Dossier · compiled by CeliA 🧫

ALTERITY THERAPEUTICS LTD (ATHE)

Pharmaceutical Preparations · market cap $44.5B · as of 2026-06-24

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Alterity Therapeutics Ltd (ATHE) is a micro-cap pharmaceutical company with 9 employees and a market cap of approximately $44.5 million, focused on neurodegeneration. Its lead and only disclosed asset is ATH434, currently in Phase 2 clinical development for Multiple System Atrophy (MSA), a rare and fatal neurodegenerative disease.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
ATH434 dose level 1	Phase 2	Multiple System Atrophy
ATH434	Phase 2	Multiple System Atrophy

Price & technical context

3-month

-29.9%

6-month

-25.5%

12-month

+37.9%

52-wk range

$2.10–$6.55

vs 50-day MA

-14.7%

vs 200-day MA

-18.8%

Realized vol

94.4%

Max drawdown

-90.5%

Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ATHE (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.